JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M201661200 on April 11, 2002

J. Biol. Chem., Vol. 277, Issue 25, 23019-23027, June 21, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/25/23019    most recent
M201661200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xie, J.
Right arrow Articles by Ma, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xie, J.
Right arrow Articles by Ma, J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

A Short Segment of the R Domain of Cystic Fibrosis Transmembrane Conductance Regulator Contains Channel Stimulatory and Inhibitory Activities That Are Separable by Sequence Modification*

Junxia XieDagger , Lynn M. AdamsDagger §, Jiying Zhao, Thomas A. GerkenDagger ||, Pamela B. DavisDagger §**, and Jianjie Ma§DaggerDagger

From the Departments of Dagger  Pediatrics, || Biochemistry, and § Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106 and the  Department of Physiology and Biophysics, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey 08854

Received for publication, February 19, 2002, and in revised form, April 10, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The regulatory (R) domain of the cystic fibrosis transmembrane conductance regulator (CFTR) contains consensus phosphorylation sites for cAMP-dependent protein kinase (PKA) that are the basis for physiological regulation of the CFTR chloride channel. A short peptide segment in the R domain with a net negative charge of B9 (amino acids 817-838, NEG2) and predicted helical tendency is shown to play a critical role in CFTR chloride channel function. Deletion of NEG2 from CFTR completely eliminates the PKA dependence of channel activity. Exogenous NEG2 peptide interacts with CFTR to exert both stimulatory and inhibitory effects on the channel function. The NEG2 peptide with sequence scrambled to remove helical tendencies also inhibits channel function, but does not stimulate. Similar results are found for a NEG2 peptide whose helical structure is disrupted by a proline residue. When six of the negatively charged carboxylic acid residues are replaced by their cognate amides, reducing net negative charge to B3, but increasing helical propensity as assessed by circular dichroism, the peptide stimulates CFTR channel function, but does not inhibit. We speculate that the NEG2 region interacts with other cytosolic domains of CFTR to control opening and closing transitions of the chloride channel.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Defects in CFTR,1 a chloride channel located in the apical membrane of epithelial cells, are associated with the common genetic disease, cystic fibrosis (1-3). CFTR is a 1480-amino acid protein that is a member of the ATP binding cassette transporter family (4). The general structure of these membrane proteins includes two membrane spanning domains, each consisting of six transmembrane segments, and two nucleotide binding folds (NBF1 and NBF2). Most members of the ATP binding cassette family use the free energy of ATP hydrolysis to actively transport substrates across the membrane (5). However, unlike the other members of this family, CFTR contains a unique regulatory (R) domain, and encodes a cAMP-regulated chloride channel (6-8).

The R domain of CFTR contains several consensus PKA phosphorylation sites (9-11) that are the basis for physiological regulation of this chloride channel. CFTR channel opening requires phosphorylation of serine residues in the R domain, and ATP binding and hydrolysis at the nucleotide binding folds (7, 12, 13). Phosphorylation adds negative charges to the R domain, and introduces global conformational changes reflected by a reduction in the alpha -helical content of the R domain protein (14). Thus, electrostatic and/or allosteric changes mediated by phosphorylation are likely responsible for interactions between the R domain and other CFTR domains that regulate channel function (15, 16).

Rich et al. (17) showed that deletion of amino acids 708-835 from the R domain (Delta R-CFTR), which removes most of the PKA consensus sites, allows the CFTR chloride channel to open without phosphorylation. The open probability of Delta R-CFTR is one-third that of the wild type (wt) CFTR channel and does not increase upon PKA phosphorylation, although other biophysical properties of the channel (i.e. conductance and anion selectivity) are similar to wt-CFTR (18, 19). These data suggest that deletion of the R domain removes both inhibitory and stimulatory effects conferred by the R domain on CFTR chloride channel function. In support of this suggestion, addition of exogenous unphosphorylated R domain protein (amino acids 588-858) to wt-CFTR blocks the chloride channel (20, 21), and the block is relieved if the R domain becomes phosphorylated, indicating that the unphosphorylated R domain is inhibitory. Conversely, exogenous phosphorylated R domain protein (amino acids 588-855 or 645-834) stimulates the Delta R-CFTR channel, suggesting that the phosphorylated R domain is stimulatory (18, 19). Therefore, it appears that the phosphorylation state of the R domain determines whether it functions to stimulate or inhibit chloride channel activity.

In this work we identify a stretch of negatively charged amino acids at the carboxyl terminus of the R domain (817-838, NEG2), with a net charge of -9, which appears to be involved in both the stimulatory and inhibitory functions of the R domain on chloride channel activity. Furthermore, by modifying the sequence of this peptide, we were able to separate its stimulatory and inhibitory functions.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Sequence alignment in NEG2 region


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Subcloning of CFTR Gene-- The wt-CFTR cDNA was cloned into an Epstein-Barr virus-based episomal eukaryotic expression vector, pCEP4 (Invitrogen, San Diego, CA), between the NheI and XhoI restriction sites (18, 20-22). The Delta NEG1 and Delta NEG2 deletion mutants were created using the pALTER mutagenesis system and shuttled from pALTER into pCEP4 by substituting the corresponding fragment in pCEP4 wt-CFTR with the mutant fragment between the BstZ171 and XhoI restriction sites. The Delta NEG1-CFTR cDNA has 27 bases deleted (amino acids 725-733). The Delta NEG2-CFTR cDNA has 66 bases deleted (amino acids 817-838). Deletions were confirmed by sequencing across the junction site.

Expression of CFTR in HEK 293 Cells-- A human embryonic kidney cell line (293-EBNA HEK; Invitrogen) was used for transfection and expression of the CFTR proteins (18, 20-22). The HEK-293 cell line contains a pCMV-EBNA vector, which constitutively expresses the Epstein-Barr virus nuclear antigen-1 (EBNA-1) gene product and increases the transfection efficiency of Epstein-Barr virus-based vectors. Cells were maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and 1% L-glutamine. Geneticin (G418, 250 µg/ml) was added to the cell culture medium to maintain selection of the cells containing the pCMV-EBNA vector. LipofectAMINE reagent (Invitrogen) in Opti-MEM media (serum-free) was used to transfect the HEK-293 cells with pCEP4(wt), pCEP4(Delta NEG1), or pCEP4(Delta NEG2). After 5 h, serum was added to the media (10% final serum concentration). Twenty-four hours after transfection, the transfection media was replaced with fresh media. The cells were harvested 2 days after transfection and microsomal membrane vesicles were prepared for single channel measurements in the lipid bilayer reconstitution system (18, 20-22).

In Vitro Phosphorylation of CFTR Proteins-- CFTR proteins isolated in membrane vesicles were bound to protein G-agarose using a mouse monoclonal anti-human CFTR antibody (mAb 24-1, Genzyme). The protein G-agarose was washed and [gamma -32P]ATP (10 µCi) and protein kinase A (~10 units/50 µl) was added. Samples were incubated at 30 °C for 1 h during phosphorylation. Excess [gamma -32P]ATP was removed, and SDS-PAGE sample buffer (200 mM Tris-Cl, pH 6.7, 9% SDS, 6% beta -mercaptoethanol, 15% glycerol, and 0.01% bromphenol blue) was added to denature CFTR and release it from the protein G-agarose. The samples were subjected to electrophoresis on a 5% SDS-polyacrylamide gel, transferred to a polyvinylidene difluoride membrane, and exposed to film. The phosphorylated proteins from 12.5-µl vesicles were loaded in each lane. Densitometry was performed and normalized to CFTR protein band intensity recorded from Western blots performed as previously described (18, 20-22) on 10-µl vesicles for wt-CFTR and the Delta NEG2-CFTR samples, and 20-µl vesicles containing Delta NEG1-CFTR, using the Genzyme 24-1 monoclonal antibody developed with ECL.

Peptide Studies-- Twenty-two residue amino acid peptides corresponding to the NEG2, NEG2i, s-NEG2, p-NEG2, and h-NEG2i sequences were custom synthesized (Quality Controlled Biochemicals, Hopkinton, MA) (see Table I). The NH2- and COOH-terminal residues of each peptide were acetylated and amidated, respectively. The peptides were determined to be >95% pure by high performance liquid chromatography mass spectral analysis. Molecular modeling was performed with Insight II software (MSI Inc., San Diego, CA) using standard amino acid side chain conformations. Secondary structure predictions were made using the secondary structure consensus prediction feature of the Network Protein Sequence analysis site at npsa-pbil.icp.fr (23, 24).

Circular dichroism (CD) spectra were obtained on a Jasco J-1810 Spectra Polarimeter (Jasco, Easton, MD) equipped with Jasco Spectra Manager (version 1.51.00) data acquisition software. Spectra were obtained at 4 °C from 1-mm path length quartz cells. CD spectra were the average of eight scans collected at 0.1-nm intervals from 260 to 190 nm using standard instrument settings. Peptide concentrations ranged between 15 and 49 µM, at pH ~ 6.7. Peptide stock solution concentrations were obtained by quantitative amino acid analysis performed by the Protein/Peptide Core Facility of the Massachusetts General Hospital.

Reconstitution of CFTR Channels in Lipid Bilayer Membranes-- Electrophysiological analysis of single channel activity was performed as previously described (17, 21). Briefly, lipid bilayer membranes were formed across an aperture of ~200 µm diameter with a mixture of phosphatidylethanolamine:phosphatidylserine:cholesterol in a ratio of 5:5:1. The lipids were dissolved in decane at a concentration of 33 mg/ml. The recording solutions contained (in mM): cis (intracellular), 200 CsCl, 1 MgCl2, 2 ATP, and 10 HEPES-Tris (pH 7.4); and trans (extracellular), 50 CsCl, 10 HEPES-Tris (pH 7.4). Vesicles (1-4 µl) containing wt-, Delta NEG1-, or Delta NEG2-CFTR were added to the cis solution. Unless otherwise noted, the PKA catalytic subunit was present at a concentration of 50 units/ml in the cis solution. Single channel currents were recorded with an Axopatch 200A patch clamp unit (Axon Instruments). The currents were sampled at 1-2.5 ms/point. Single channel data analyses were performed with pClamp and TIPS software.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Activity of CFTR Channels Lacking the NEG1 or NEG2 Sequence-- Examination of the primary amino acid sequence of CFTR revealed two regions with high proportion of negatively charged residues in the R domain, amino acids 725-733 (NEG1) and amino acids 817-838 (NEG2) (Fig. 1A). The NEG2 sequence is highly conserved across species (Table I). To investigate the roles of NEG1 and NEG2 in CFTR function, these regions were deleted from CFTR. The resulting Delta NEG1- and Delta NEG2-CFTR proteins were transiently expressed in HEK 293 cells. Membrane vesicles containing CFTR proteins were isolated and subjected to SDS-PAGE. Like wt-CFTR, both Delta NEG1- and Delta NEG2-CFTR are present both in the core glycosylated (band B) and the fully glycosylated form (band C) (Fig. 1B). The PKA dependence of the Delta NEG1-CFTR channel is similar to wt-CFTR (Fig. 1C). No channel activity is observed in the absence of PKA, and the open probability (Po) of the Delta NEG1-CFTR channel in the presence of PKA and ATP is similar to wt-CFTR. In contrast, the Delta NEG2-CFTR channel opens without PKA (Fig. 1C, right). The "constitutive" activity of the Delta NEG2-CFTR channel is unlikely to be due to the endogenous phosphorylation of the Delta NEG2-CFTR protein, since protein phosphatase 2A, which decreases activity of the wt-CFTR opened by PKA and ATP (18), has no effect on the Delta NEG2-CFTR channel (n = 4). Moreover, addition of PKA up to 200 units/ml, four times the concentration required to fully activate wt-CFTR (18), does not increase the open probability of the Delta NEG2-CFTR channel (Fig. 2). Although the conductance properties of Delta NEG2-CFTR are similar to those of wild type CFTR (25), its open probability is much less and cannot be increased with PKA (wt-CFTR Po = 0.254 ± 0.024, n = 11; Delta NEG2-CFTR, Po = 0.061 ± 0.015 without PKA and 0.053 ± 0.016, with PKA, n = 8).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 1.   Properties of CFTR with the NEG1 or NEG2 sequence deleted. A, amino acid sequences of NEG1 and NEG2. B, autoradiograms illustrating in vitro phosphorylation of wt-, Delta NEG1-, and Delta NEG2-CFTR by PKA in the presence of [gamma -32P]ATP. Both the core (band B) and fully glycosylated (band C) forms of all three CFTR molecules are phosphorylated. Identical amounts of protein (7.5 µg) were loaded in each lane. C, single channel currents of wt-, Delta NEG1-, and Delta NEG2-CFTR separately incorporated into the lipid bilayer. While the activity of wt- (left) and Delta NEG1-CFTR (middle) absolutely require PKA in the cis-intracellular solution, the Delta NEG2-CFTR channel opens without PKA phosphorylation (right). Furthermore, activity of the Delta NEG2-CFTR channel does not change with PKA phosphorylation (right).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 2.   Diary plot of open probability of the Delta NEG-2-CFTR channel. Recording begins with channel stimulated with 50 units/ml PKA and 2 mM ATP on the cis (intracellular) side. At the arrow, the amount of PKA was increased to 100 units/ml, and at the second arrow, to 200 units/ml. After mixing of the additions in the solution, open probability of the channel did not change. This plot is representative of three other experiments.

The failure of the Delta NEG2-CFTR channel to respond to PKA does not result from inability of the channel to be phosphorylated, an in vitro assay using [gamma -32P]ATP shows comparable phosphorylation of wt-CFTR and Delta NEG2-CFTR (Fig. 1B). Densitometry readings for this gel were: wt-CFTR, Band C, 1063 units, Band B, 818 units; Delta NEG2-CFTR, Band C, 1000 units, Band B, 1145 units. However, since expression of Delta NEG2-CFTR in vesicles was slightly less than wt-CFTR, on Western blot, values for phosphorylated protein normalized to the amount of CFTR present were slightly higher for the Delta NEG2-CFTR. Densitometry units of radioactive phosphate per densitometry unit of ECL-labeled CFTR on Western blot for identical amounts of vesicles were as follows: for wt-CFTR, Band C, 1.3, Band B, 1.16; for Delta NEG2-CFTR, Band C, 1.58, Band B, 2.38. In a second experiment, the values were: wt-CFTR, Band C, 1.15, Band B, 0.99; for Delta NEG2-CFTR, Band C, 1.62, Band B, 2.08. Thus, Delta NEG2-CFTR was at least as well phosphorylated as the wt-CFTR under these conditions. The apparent molecular weight of the phosphorylated Delta NEG-2 CFTR protein is less than that of the wild type protein or the Delta NEG1-CFTR (apparent Mr 169,000 for wild type-CFTR Band C versus 160,000 for the Delta NEG1-CFTR Band C versus Mr 155,000 for the Delta NEG2-CFTR Band C). The apparent reduction in molecular weight with deleting these negatively charged sequences is greater than can be accounted for by the mass of the amino acids alone. This difference probably results from the deletion of substantial negative charges along with the sequence, since disproportion of acidic amino acids, especially when concentrated in a short sequence, is well known as a cause of anomalously high molecular weight determinations in SDS-PAGE (26-28).

The Delta NEG2-CFTR channel still contains all 10 consensus PKA phosphorylation sites. Riordan and co-workers (29, 30) showed that even wt-CFTR with all 10 consensus PKA sites mutated increases its Po in response to PKA, presumably by phosphorylation of a weak consensus sequence at Ser753. Elimination of PKA responsiveness is therefore an unusual property of the Delta NEG2-CFTR channel. Since the Delta NEG2-CFTR channel exhibited reduced Po, it is possible that removal of the NEG2 sequence also alters the stimulatory function of the R domain on the CFTR channel. To test this possibility, the following experiments were performed.

Structural Properties of the NEG2 Sequence-- NEG2 is predicted to have high alpha -helical content by several secondary structure prediction algorithms (23, 24). Molecular modeling of the NEG2 sequence as an alpha -helix reveals a long negatively charged stripe circling the helix, paralleled by two hydrophobic patches (Fig. 3A). To distinguish the effect of bulk negative charge from that of a specific structural motif due to this putative helical conformation, several sequence variant peptides were designed with different predicted helical propensities (Table II). To retain the negative charge but disrupt the helix, we synthesized a scrambled NEG2 peptide (s-NEG2) containing the same amino acids but designed to disrupt the alpha -helical content; and in a second variant, we inserted a proline residue into the sequence to disrupt the helical structure (p-NEG2). To reduce the negative charge, but retain the helical structure, four aspartic acid residues were replaced with asparagines, and two glutamic acid residues were replaced with glutamines, as well as substituting serine for the native cysteine residue (Cys832) to avoid disulfide cross-linking of the peptide and replacing the native methionine (Met837) with norleucine to avoid oxidation. The resulting peptide was designated h-NEG2i for helical NEG2-inert. The h-NEG2i peptide has net negative charge of -3, but is predicted to have strong helical propensity (Table II). An attempt to replace all of the aspartic acid and glutamic acid residues with their cognate amides resulted in an insoluble peptide. In addition, we obtained an inert NEG2 variant, NEG2i, with the cysteine to serine and methionine to norleucine substitutions, to assure that the structural changes we observed in h-NEG2i were not the result of these substitutions.


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 3.   Structure of wt NEG2 peptide and CD spectroscopy of NEG2 peptide analogues. A, space filling model of the predicted alpha -helical structure of the NEG2 peptide. The negatively charged Glu and Asp residues are colored purple, the hydrophoblic residues Leu, Ile, and Phe are orange, and Lys, light blue. The remaining residues are gray. B-E, circular dichroism spectra of NEG2i (pink), h-NEG2i (blue), s-NEG2 (light blue), p-NEG2 (red), and NEG2 (green) at 0, 33, 50, and 66% TFE in water at pH 6.7. F and G, mean residue molar ellipticity plots at 193 and 222 nm for the peptides as a function of TFE. Percent helicity was estimated from the band intensities using the maximum helical values of Chen et al. (32).

                              
View this table:
[in this window]
[in a new window]
 
Table II
Properties of peptides based in sequence on NEG2

Circular dichroism spectra obtained in aqueous solution of increasing concentrations of trifluoroethanol (TFE, 0-66%) were used to assess the helical propensities of these peptides (Fig. 3, panels B-E). There was little or no helical tendency of the p-NEG2 or s-NEG2 peptides in the presence or absence of TFE as demonstrated by the lack of characteristic positive and negative alpha -helical bands at 193 and 222 nm, respectively (Fig. 3, panels F and G). Instead the large negative bands at 200 nm suggest predominantly random coil structures for these peptides (31). The NEG2 and NEG2i peptides demonstrate relatively little helicity in aqueous solution, however, with increasing TFE concentration, the helical content steadily increases as shown by the increase in the characteristic helical bands at 193 and 222 nm. Interestingly, h-NEG2i has clear helical tendency in the absence of TFE, which can be further enhanced by TFE addition (Fig. 3, F and G). Mean residue molar ellipticity plots at 193 and 222 nm for these peptides as a function of TFE concentration are given in Fig. 3, F and G, as well as estimates of percent helicity (32). These plots clearly indicate that h-NEG2i is significantly more helical than NEG2 or NEG2i and that s-NEG2 and p-NEG2 almost completely lack helical structures. The different helical propensities between NEG2 and s-NEG2 were also confirmed by two-dimensional NOESY proton NMR spectroscopy.

Effect of Exogenous NEG2 and Its Congeners on CFTR Channel Activity-- To test whether the NEG2 region is responsible for both stimulatory and inhibitory interactions between the R domain and other domains of CFTR, the wild type NEG2 peptide was added to the cis-intracellular side of a single CFTR channel captured in the planar lipid bilayer (Fig. 4). The diary plot of Po as a function of time shows the activity of a single wt-CFTR channel during the course of the experiment (Fig. 4). After peptide addition (at arrows), there are periods of intense stimulation that last 4-8 min, often followed by return to the basal level of activity observed before peptide addition. In the example shown, activity reverted to baseline levels 4-8 min after addition of NEG2 peptide at concentrations 2.2 and 4.4 µM, but at 8.8 µM, stimulation persisted until a still higher concentration was added, at which time the channel closed. At higher concentrations, NEG2 produces an almost complete inhibition of the channel, where only a flickery 3 pS conductance is observed. During stimulation, the open probability more than doubled and more transitions were observed between the open and closed states (Fig. 4). In 10 of 12 experiments in which a peptide concentration >= 0.44 µM was achieved, a stimulatory response was observed. For the two experiments for which it was not, one channel was inhibited upon initial peptide addition at a concentration of 4.4 µM and no stimulation was observed, and another channel did not display stimulation. Statistically significant increases in channel open probability are documented for NEG2 concentrations of 4.4 and 8.8 µM, and increased activity, with p = 0.09, was observed at 2.2 µM NEG2. Profound inhibition, comparable with that shown in the example, was observed in five channels exposed to NEG2 peptide at concentrations >= 4.4 µM. However, in five other channels treated with NEG2 peptide at a concentration >= 4.4 µM, inhibition did not occur, even at concentrations up to 26.4 µM. For some of these experiments, the channel may not have survived long enough in the bilayer following addition of peptide to be confident of lack of inhibition. Nevertheless, at the highest concentrations of peptide tested, 13.2 and 26.4 µM, statistically significant inhibition was achieved when all channel recordings are considered.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 4.   Stimulation and inhibition of wt-CFTR channel by the exogenous NEG2 peptide. Diary plot (open probability versus time) of a wt-CFTR channel reconstituted into lipid bilayer membrane, illustrating the effect of the NEG2 peptide on channel activity. The cis-intracellular solution contained 2 mM ATP and 50 units PKA/ml. Arrows indicate the time when the peptides were added to the recording solution. The concentration of NEG2 is indicated above the plot. Representative single channel currents are shown at -80 mV, illustrating the stimulatory and inhibitory effects of the NEG2 peptide on wt-CFTR. This diary plot is from one of 12 experiments with the wt-CFTR channel. Stimulation was observed in 10 of the 12, and inhibition, in 5 of 10 in which the channel survived to be tested at concentrations >= 4.4 µM. For stimulation, eight paired experiments were performed at 4.4 µM NEG2, for which baseline Po was 0.234 ± 0.023 and stimulated Po was 0.340 ± 0.032 (p = 0.0097). Statistically significant stimulation of channel activity was also observed in paired experiments for concentrations of 8.8 µM (n = 6, p = 0.017). Due to the sporadic nature of channel inhibition by the NEG2 peptide, statistically significant inhibitory effects were only observed at concentrations of 13.2 µM (n = 9, Po at baseline 18.8 ± 1.6%, and with 13.2 µM NEG 2, 4.5 ± 0.9%, p < 0.0001) and 26.4 µM (n = 5, p < 0.0001).

Because inhibition did not occur with every experiment when the NEG2 peptide was added to the wt-CFTR channel, we speculated that there might be competition from the endogenous NEG2 sequence for the binding sites, and the endogenous sequence might have the advantage of presentation and proximity. We therefore tested the Delta NEG-2-CFTR channel for its ability to undergo stimulation or inhibition by the exogenous NEG2 peptide. The NEG2 peptide at concentrations 2.2 to 4.4 µM significantly stimulates the Delta NEG2-CFTR channel activity, but at higher concentrations, ranging from 2.2 to 13.2 µM, the channel is markedly inhibited (Fig. 5). The NEG2-peptide-induced increase in Delta NEG2-CFTR channel activity results almost entirely from an increase in channel openings, from 2.14 ± 0.42 openings/s to 3.94 ± 1.04 openings/s after application of 2.2 µM NEG2, whereas the reduction of channel activity at higher NEG2 peptide concentrations is due to a combination of decrease in channel open lifetime and decrease in channel open events. Inhibition of channel activity occurred in seven of eight experiments in the absence of PKA, and in all three experiments performed in its presence.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 5.   Stimulation and inhibition of Delta NEG-2-CFTR channel by NEG2 peptide. A, sample traces of channel activity in the absence and presence of 2.2 µM NEG2 peptide, with PKA in the cis chamber. These data are representative of a total of nine experiments, in which Po increased from 0.072 ± 0.01 in the control recordings to 0.121 ± 0.02 in the presence of 2.2 µM NEG2 peptide (p < 0.015). Significant stimulation was also observed at 4.4 µM NEG2 (p = 0.025, n = 9). B, diary plot of a representative experiment in which increasing concentrations of NEG2 peptide were added to the cis (intracellular) side of the channel. Each data point represents the averaged Po calculated from a complete file consisting of 16 episodes of test pulses to -80 mV (10 s duration) from a holding potential of 0 mV. The interval between each test pulse was 10 s at 0 mV. The channel activities at 0 mV were not included in the calculation of Po. This diary plot is taken from an experiment performed without PKA present in the cis solution. When PKA was absent from the system, Delta NEG2-CFTR activity was inhibited in eight of nine experiments at an average concentration of 4.3 µM NEG2 peptide. The control Po was 0.09 ± 0.017, and Po in the presence of NEG2 peptide was 0.022 ± 0.005 (p = 0.0001, n = 9). When PKA was present (50 units/ml), the Delta NEG2-CFTR channel was inhibited in three of three experiments at an average concentration of 12.5 µM NEG2 peptide.

To elucidate the mechanism responsible for the increase in Po at the lower peptide concentrations, the gating kinetics of wt-CFTR without peptide and during stimulation by NEG2 peptide were analyzed. The open time distributions of the wt-CFTR did not change during peptide stimulation, as both control (without NEG2 peptide) and peptide-stimulated channels had an open lifetime of ~120 ms (Fig. 6A). Thus, the increase in Po is not due to a change in the closing rate of the channel. However, the closed time distribution for the stimulated channel is clearly shifted to the left compared with the control channel (Fig. 6, B and C). There are three components to the closed state, a fast (tc1), an intermediate (tc2), and a long (tc3) closed component. Following peptide stimulation, the intermediate closed time was reduced significantly, from 459 to 105 ms (p < 0.005). The long closed time was also shortened, but because of the variability in the measurements (and their paucity in the stimulated condition), this did not achieve statistical significance. However, there were significantly fewer episodes in the long closed time category in the presence of the NEG2 peptide. Thus, the channel opening rate has increased in the presence of the NEG2 peptide, and this appears to account for the increase in Po of the channel (Fig. 6D). This mechanism is similar to what we, and others, observe for phosphorylated R domain protein (amino acids 588-855 or 645-834) when it stimulates the wt-CFTR channel (18, 19).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 6.   Kinetic analysis of CFTR channels stimulated by NEG2 peptide. A-C show histograms of open and closed events of the wt-CFTR channel at -80 mV, generated under control conditions (left) and after addition of 4.4 µM NEG2 peptide to the cis-solution (right). The open time histograms (A) contain a single exponential component with a time constant of 124 ms (control) and 105 ms (peptide-stimulated) (top), values not significantly different from one another. The closed time histograms (B) contain a fast component and multiple slow components (middle). The fast component is probably due to closings within a burst (33). Therefore, to better identify the closed times between bursts, a delimiter of tc = 40 ms was set at the nadir between the fast and intermediate closed times (arrow) to generate the closed-burst duration histograms (C). The solid lines represent the fit according to a double exponential equation: y = P2*exp[t-a2-exp(t-a2)] + P3*exp[t-a3-exp(t-a3)], where a2 = log tc2, a3 = log tc3, P2 = probability of the intermediate closed component, and P3 = probability of the long closed component. The best fit parameters are P2 = 0.811, tc2 = 459 ms, P3 = 0.189, tc3 = 2494 ms (control); P2 = 0.957, tc2 = 105 ms, P3 = 0.043, tc3 = 1652 ms (peptide-stimulated). Changes in Po and tc2 of the wt-CFTR channel in paired experiments, before and after addition of 4.4 µM wt-NEG2 peptide is shown in D.

The s-NEG2 peptide has no stimulatory effect on the wt-CFTR channel, but exhibits inhibition on the wt-CFTR channel (Fig. 7A). In paired experiments, the wt-CFTR channel has an average Po of 0.266 ± 0.034 (n = 6) under control conditions of 2 mM ATP and 50 units/ml PKA in the intracellular solution. With the addition of as little as 0.44 µM s-NEG2 peptide, the Po was reduced by 70%, and with 2.2 µM s-NEG2, the inhibition was 80% (Fig. 7A). The NEG2 peptide with a proline residue inserted in the sequence to disrupt the helical conformation, p-NEG2, also produced significant channel inhibition (60% at 11 µM) (Fig. 7B). Inhibition of wt-CFTR has also been reported with the NEG1 peptide (which carries a total negative charge of -6) by other investigators (33). Thus, it is likely that charge interactions contribute to the inhibitory effects of the exogenous peptides on the CFTR channel.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 7.   Maintaining the negative charge, but disrupting the alpha -helical content of NEG2 peptide results in inhibition without stimulation of CFTR channel function. A, representative single channel current traces from a wt-CFTR channel, illustrating the inhibitory effects of s-NEG2. Data from 6 paired experiments with s-NEG2 are summarized in the bottom panel. Po = 0.266 ± 0.034, control; 0.051 ± 0.010, +s-NEG2 (p < 0.005). B, various concentrations of p-NEG2 peptide all inhibited the wt-CFTR channel, without stimulatory effects. Summary of changes in Po from five paired experiments: Po = 0.235 ± 0.029, control; 0.194 ± 0.043, +2.2 µM p-NEG2 (p = NS); 0.108 ± 0.023, +11 µM p-NEG2 (p < 0.02).

To further dissect the stimulatory and inhibitory effects of the NEG2 sequence, we synthesized another peptide, h-NEG2i, in which negative charge was reduced from -9 to -3 (Table I). As shown in Fig. 3C, the h-NEG2i peptide exhibits higher propensity of alpha -helical structure in aqueous solution. At the single channel level, h-NEG2i gave persistent concentration-dependent stimulation of the wt-CFTR without inhibitory activity (Fig. 8). With the addition of 3.6 µM h-NEG2i peptide to the wt-CFTR channel, the channel open probability increased from 0.228 ± 0.040 to 0.459 ± 0.044 (n = 5 paired experiments) (Fig. 8). The mechanism of stimulation, like that of wt-NEG2, was not due to an increase in mean open life time but through the reduction of closed time of the channel. The number of open events per second was 2.43 ± 1.05 in the control state, but increased to 4.75 ± 0.79 in the presence of hNEG2i (p < 0.01, n = 5). Unlike the other constructs of NEG2 peptide, h-NEG2i has no inhibitory effect on wt-CFTR at concentrations as high as 16.5 µM. The overall effects of the various NEG2 peptides on the wt-CFTR channel are summarized in Table II.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 8.   Increasing the alpha -helical content and decreasing the negative charge of NEG2 peptide result in persistent activation without inhibition of the CFTR channel. A, representative single channel current traces are plotted for wt-CFTR at -80 mV testing potential before (Control) and after the addition of 0.66 µM h-NEG2i (+h-NEG2i) to the cis-solution. Persistent activation of the CFTR channel was observed at concentrations ranging from 0.33 to 11.2 µM h-NEG2i. B, summary of data from five paired experiments, demonstrating that the average Po increased from 0.228 ± 0.040 to 0.459 ± 0.044 (n = 5, p < 0.01) with the addition of 3.3 µM h-NEG2i. C, mean open lifetime of wt-CFTR channel does not change as a result of h-NEG2i stimulation: tau o = 151.7 ± 25.2 ms, control; 184.2 ± 22.1, +3.3 µM h-NEG2 (p = NS).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The R domain of CFTR contains two negatively charged regions, amino acids 725-733 (NEG1) and amino acids 817-838 (NEG2) which reside in close proximity to two PKA phosphorylation sites, Ser737 and Ser813, that are used in vivo (9). One amino acid substitution, noted in a patient with CF, is reported in the CF Mutation Consortium data base in the NEG1 region (E725K). Three mutations are reported in the NEG2 region (E822K, E826K, and D836Y), two of which were obtained from patients with cystic fibrosis (E822K and D836Y). Single channel studies of E822K and E826K indicate that both mutations result in reduced Po compared with wt-CFTR (34). Moreover, Cotten and Welsh (35) showed that N-ethylmaleimide modification of a cysteine residue in the NEG2 region (C832) produced irreversible stimulation of PKA-phosphorylated CFTR channel activity. The NEG2 region is highly conserved among species. Taken together, these data indicate the importance of this portion of the R domain for the regulation of the CFTR channel. Our data demonstrate that the NEG2 region of CFTR can both stimulate and inhibit chloride channel function. When this region is deleted from CFTR, the resultant channel opens without PKA, indicating loss of inhibitory function, but the Po never achieves that of wt-CFTR, and does not increase when phosphorylated with PKA, indicating a loss of stimulatory function. In support of a dual action for the NEG2 sequence, addition of the NEG2 sequence as a synthetic peptide to the intracellular side of the CFTR channel results in stimulation of channel openings at lower concentrations, but inhibition of channel activity at higher concentrations.

Stimulatory and inhibitory activities can be separated by sequence modifications. Inhibition alone is evident with peptides designed to retain the negative charge but disrupt the helical tendencies. Conversely, stimulation occurs with a peptide designed to retain and enhance the helical structure of the sequence, but to reduce the negative charge. Molecular modeling reveals an amphipathic feature of the NEG2 sequence, i.e. the negatively charged residues mostly line up as a barber-pole stripe on the alpha -helix. The surrounding residues are mostly hydrophobic. We speculate that the NEG2 sequence, presented in different ways, could interact with CFTR at different sites to either stimulate or inhibit channel openings. Which function the NEG2 sequence performs might be determined by how it is presented in the context of the intact molecule, which could be entrained, at least in part, by the phosphorylation state of the R domain. In this model, phosphorylated R domain favors presentation of the hydrophobic stripe of the helical conformation of NEG2 to the stimulatory site, whereas the unphosphorylated R domain favors access of the negative charge in NEG2 to an inhibitory site. Since the mechanism of increasing channel activity appears to be, both for NEG2 and for h-NEG2i, mainly by increasing the number of channel openings, we speculate that the stimulatory activity might result from peptide binding increasing either binding or hydrolysis of ATP, probably at the first nucleotide-binding domain, which is often assigned the role of channel opening (36).

When the exogenous NEG2 peptide is added to the intracellular side of the wt-CFTR channel, it could interact with either the stimulatory site or the inhibitory site, and it may compete with the endogenous sequence for access to these sites. The degree and duration of stimulation or inhibition by exogenous peptide will depend on the on and off rates at the stimulatory site and the inhibitory site, the effective concentration of the relevant structural form of the peptide, and competition from endogenous sequences (either the NEG2 sequence itself, or sequences at other sites) at those two sites. When the channel is closed, as it is most of the time even in the phosphorylated state (since the Po is only about 30%), the endogenous site for inhibition may often be occupied by the endogenous NEG2 sequence, and thus binding of the exogenous peptide is favored at the stimulatory site. However, as stimulation increases, the inhibitory site may become more available, and eventually binding occurs at this site, and the channel is inhibited.

Naren and co-workers (37) reported that a sequence in the NH2 terminus of CFTR interacts with sequences in the proximal end of the R domain to increase CFTR channel activity. This work, taken together with the work reported here, is consistent with our earlier studies of segments of the R domain which inhibit channel function (21). Two segments, one containing amino acids 588-805 and the other, amino acids 672-855, proved inhibitory. The first segment may inhibit channel activity by interacting with the stimulatory NH2-terminal sequence in CFTR, preventing it from interacting with its target in the R domain, thereby preventing channel stimulation. The second inhibitory segment contains the NEG2 sequence, and probably inhibits channel openings by presenting NEG2 to its inhibitory site. It is intriguing that the binding portion of the NH2 terminus, which stimulates channel activity, appears to be a helical segment of the protein with one negatively charged face, and its activity is abrogated by reducing the negative charges in this segment (38). This observation reinforces the concept that negatively charged sequences may exert profound regulatory influence on channel activity.

A recent study by Baldursson et al. (39) found that deletion of amino acids 760-783 in the R domain resulted in CFTR channel activity in the absence of PKA phosphorylation; however, deletion of amino acids 784 to 835, which includes most of the NEG2 sequence, did not allow the channel to open without phosphorylation. It may be that the two deletion mutants delete the NEG2 sequence in whole or in part, ours (Delta NEG2(817-838)-CFTR) and that of Baldursson et al. (39) (Delta (784-835)-CFTR), assume different conformations compared with the native CFTR molecule and thus may behave differently in channel function. Baldursson's (39) construct deletes 33 more amino acids (amino acids 783-816, including a putative PKC-phosphorylation site (Ser790)) than our Delta NEG2-CFTR construct. Since PKC phosphorylation has an essential role in PKA phosphorylation-dependent regulation of the CFTR channel (40), removal of this site may alter channel regulation. The potential role of PKC phosphorylation on the Delta (784-835)-CFTR and Delta (817-838)-CFTR remains to be studied. It is also possible that the R domain contains more than one inhibitory site, or both identified segments of R domain sequences (760-783 and 817-838) could act together to inhibit the unphosphorylated CFTR channel, and the lack of either one disrupts the inhibitory function of the R domain. King and Sorscher (41) also identify the COOH-terminal portion of the R domain (amino acids 723-836, which includes both the putative inhibitory sequences) as crucial in conferring PKA regulation on the channel.

Future studies to identify the sites of NEG2 interaction within the CFTR molecule should provide new insights into the regulation of the CFTR channel. Particularly, understanding the stimulatory interaction of NEG2 may facilitate the design of therapeutics to stimulate the CFTR opening to treat patients whose mutant forms of CFTR reach the cell surface.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants RO1 HL/DK 49003 and P30 DK27651 (to P. B. D.), RO1 DK51770 (to J. M.) and grants from the Cystic Fibrosis Foundation (to J. M., P. B. D., and T. A. G.) and National Institutes of Health Grant T32 HL07415 (to P. B. D.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence may be addressed: Dept. of Pediatrics, Case Western Reserve University School of Medicine, 10900 Euclid Ave., Cleveland, OH 44106. Tel.: 216-368-4370; E-mail: pbd@po.cwru.edu.

Dagger Dagger To whom correspondence may be addressed: Dept. of Physiology and Biophysics, UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854. Tel.: 732-235-4494; E-mail: maj2@umdnj.edu.

Published, JBC Papers in Press, April 11, 2002, DOI 10.1074/jbc.M201661200

    ABBREVIATIONS

The abbreviations used are: CFTR, cystic fibrosis transmembrane conductance regulator; TFE, trifluoroethanol; EBNA-1, Epstein-Barr virus nuclear antigen-1.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Quinton, P. M. (1986) Am. J. Physiol. 251, C649-C652
2. Welsh, M. J., and Smith, A. E. (1993) Cell 73, 1251-1254
3. Zielenski, J., and Tsui, L. C. (1995) Annu. Rev. Genet. 29, 777-807
4. Riordan, J., Rommens, J., Kerem, B.-S., Noa, A., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., Drumm, M., Iannuzzi, M., Collins, F., and Tsui, L.-C. (1989) Science 245, 1066-1073
5. Higgens, C. F. (1992) Annu. Rev. Cell Biol. 8, 67-113
6. Bear, C. E., Li, C., Kartner, N., Bridges, R. J., Jensen, T. J., Ramjeesingh, M., and Riordan, J. R. (1992) Cell 68, 809-818
7. Anderson, M. P., Berger, H. A., Rich, D. P., Gregory, R. J., Smith, A. E., and Welsh, M. J. (1991) Cell 67, 775-784
8. Ma, J., and Davis, P. B. (1998) Clin. Chest Med. 19, 459-471
9. Rich, D. P., Berger, H. A., Cheng, S. H., Travis, S. M., Saxena, M., Smith, A. E., and Welsh, M. J. (1993) J. Biol. Chem. 268, 20259-20267
10. Picciotto, M. R., Cohn, J. A., Bertuzzi, G., Greengard, P., and Nairn, A. C. (1992) J. Biol. Chem. 267, 12742-12752
11. Cheng, S. H., Rich, D. P., Marshall, J., Gregory, R. J., Welsh, M. J., and Smith, A. E. (1991) Cell 66, 1027-1036
12. Tabcharani, J. A., Chang, X.-B., Riordan, J. R., and Hanrahan, J. W. (1991) Nature 352, 628-631
13. Gunderson, K. L., and Kopito, R. R. (1995) Cell 82, 231-239
14. Dulhanty, A. M., and Riordan, J. R. (1994) Biochemistry 22, 4072-4079
15. Ma, J. (2000) News Physiol. Sci. 15, 154-158
16. Wilkinson, D. J., Strong, T. J., Mansoura, M. K., Woud, D. L., Smith, S. S., Collins, F., and Dawson, D. C. (1997) Am. J. Physiol. 273, L127-L133
17. Rich, D. P., Gregory, R. J., Anderson, M. P., Manavalan, P., Smith, A. E., and Welsh, M. J. (1991) Science 253, 205-207
18. Ma, J., Zhao, J., Drumm, M. L., Xie, J., and Davis, P. B. (1997) J. Biol. Chem. 272, 28133-28141
19. Winter, M. C., and Welsh, M. J. (1997) Nature 389, 294-296
20. Ma, J., Tasch, J. E., Tao, T., Zhao, J., Xie, J., Drumm, M. L., and Davis, P. B. (1996) J. Biol. Chem. 271, 7351-7356
21. Tasch, J. E., Zerhusen, B., Zhao, J., Ma, J., and Davis, P. B. (1999) FEBS Lett. 445, 63-68
22. Xie, J., Drumm, M. L., Ma, J., and Davis, P. B. (1995) J. Biol. Chem. 270, 28084-28091
23. Geourjon, C., and Deleage, G. (1995) Comput. Appl. Biosci. 11, 681-684
24. Rost, B., and Sander, C. (1994) Proteins 19, 55-72
25. Tao, T., Xie, J., Drumm, M. L., Zhao, J., Davis, P. B., and Ma, J. (1996) Biophys. J. 70, 743-753
26. Iakoucheva, L. M., Kimzey, A. L., Masselon, C. D., Smith, R. D., Dunker, A. K., and Ackerman, E. J. (2001) Protein Sci. 10, 1353-1362
27. Armstrong, D. J., and Roman, A. (1993) Biochem. Biophys. Res. Commun. 192, 1380-1387
28. Graceffa, P., Jancso, A., and Mabuchi, K. (1992) Arch. Biochem. Biophys. 297, 46-51
29. Chang, X. B., Tabcharani, J. A., Hou, Y. X., Jensen, T. J., Kartner, N., Alon, N., Hanrahan, J. W., and Riordan, J. R. (1993) J. Biol. Chem. 268, 11304-11311
30. Seibert, F. S., Tabcharani, J. A., Chang, X. B., Dulhanty, A. M., Mathews, C., Hanrahan, J. W., and Riordan, J. R. (1995) J. Biol. Chem. 270, 2158-2162
31. Perczell, A., Park, K., and Fasman, G. D. (1992) Proteins Struct. Funct. Genet. 13, 7-69
32. Chen, Y.-H., Yang, J. T., and Chau, K. H. (1974) Biochemistry 13, 3350-3359
33. Ikuma, M., Baldursson, O., Ostedgaard, L. S., and Welsh, M. J. (1999) Pediatr. Pulmonol. Suppl. 19, 176 (abstr.)
34. Vankeerberghen, A., Wei, L., Jaspers, M., Cassiman, J.-J., Nilius, B., and Cuppens, H. (1998) Hum. Mol. Genet. 7, 1761-1769
35. Cotten, J. F., and Welsh, M. J. (1997) J. Biol. Chem. 272, 25617-25622
36. Carson, M. R., Travis, S. M., and Welsh, M. J. (1995) J. Biol. Chem. 270, 1711-1717
37. Naren, A. P., Cormet-Boyaka, E., Fu, J., Villain, M., Blalock, J. E., Quick, M. W., and Kirk, K. L. (1999) Science 286, 544-548
38. Fu, J., Ji, H-L., Naren, A. P., and Kirk, K. L. (2001) J. Physiol. 536, 459-470
39. Baldursson, O., Ostedgaard, L. S., Rokhlina, T., Cotton, J. F., and Welsh, M. J. (2001) J. Biol. Chem. 276, 1904-1910
40. Jia, Y., Mathew, C. J., and Hanrahan, J. W. (1997) J. Biol. Chem. 272, 4978-4984
41. King, S. A., and Sorscher, E. J. (2000) Biochemistry 39, 9869-9875


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
G. Seavilleklein, N. Amer, A. Evagelidis, F. Chappe, T. Irvine, J. W. Hanrahan, and V. Chappe
PKC phosphorylation modulates PKA-dependent binding of the R domain to other domains of CFTR
Am J Physiol Cell Physiol, November 1, 2008; 295(5): C1366 - C1375.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. M. Lewarchik, K. W. Peters, J. Qi, and R. A. Frizzell
Regulation of CFTR Trafficking by Its R Domain
J. Biol. Chem., October 17, 2008; 283(42): 28401 - 28412.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S. Gupta, J. Xie, J. Ma, and P. B. Davis
Intermolecular Interaction Between R Domains of Cystic Fibrosis Transmembrane Conductance Regulator
Am. J. Respir. Cell Mol. Biol., February 1, 2004; 30(2): 242 - 248.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/25/23019    most recent
M201661200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal